161 related articles for article (PubMed ID: 30694216)
1. Association between antidiabetic agents use and leukocyte telomere shortening rates in patients with type 2 diabetes.
Liu J; Ge Y; Wu S; Ma D; Xu W; Zhang Y; Yang Y
Aging (Albany NY); 2019 Jan; 11(2):741-755. PubMed ID: 30694216
[TBL] [Abstract][Full Text] [Related]
2. The Association between Antidiabetic Agents and Leukocyte Telomere Length in the Novel Classification of Type 2 Diabetes Mellitus.
Huang J; Peng X; Dong K; Tao J; Yang Y
Gerontology; 2021; 67(1):60-68. PubMed ID: 33321495
[TBL] [Abstract][Full Text] [Related]
3. Insulin treatment affects leukocyte telomere length in patients with type 2 diabetes: 6-year longitudinal study.
Zeng JB; Liu HB; Ping F; Li W; Li YX
J Diabetes Complications; 2019 May; 33(5):363-367. PubMed ID: 30857946
[TBL] [Abstract][Full Text] [Related]
4. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
Hanefeld M; Schaper F; Koehler C; Bergmann S; Ugocsai P; Stelzer J; Schmitz G
Horm Metab Res; 2009 Feb; 41(2):132-6. PubMed ID: 19214923
[TBL] [Abstract][Full Text] [Related]
5. Mean leukocyte telomere length shortening and type 2 diabetes mellitus: a case-control study.
Zee RY; Castonguay AJ; Barton NS; Germer S; Martin M
Transl Res; 2010 Apr; 155(4):166-9. PubMed ID: 20303464
[TBL] [Abstract][Full Text] [Related]
6. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus.
Su B; Liu H; Li J; Sunli Y; Liu B; Liu D; Zhang P; Meng X
J Diabetes; 2015 Sep; 7(5):729-39. PubMed ID: 25327485
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review.
Derosa G; Maffioli P
Clin Ther; 2012 Jun; 34(6):1221-36. PubMed ID: 22560622
[TBL] [Abstract][Full Text] [Related]
8. Can Antidiabetic Medications Affect Telomere Length in Patients with Type 2 Diabetes? A Mini-Review.
Qin B
Diabetes Metab Syndr Obes; 2023; 16():3739-3750. PubMed ID: 38028989
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
[TBL] [Abstract][Full Text] [Related]
10. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
11. [Robert Koch Award for acarbose. Antidiabetic drug prevents myocardial infarct].
MMW Fortschr Med; 2003 Feb; 145(6):59. PubMed ID: 12619367
[No Abstract] [Full Text] [Related]
12. [Changes in metabolic parameters and microalbuminuria in patients with type 2 diabetes treated with acarbose].
González Sarmiento E; Ergueta Martín P; Fernández Martínez I; Hinojosa Mena-Bernal MC; Zurro Muñoz I; Zurro Hernández J
An Med Interna; 2001 May; 18(5):234-6. PubMed ID: 11496556
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
15. Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus.
Wang RR; Lv ZM; Dan YP; Chen KY; Zhang C
J Biol Regul Homeost Agents; 2019; 33(2):365-374. PubMed ID: 30972995
[TBL] [Abstract][Full Text] [Related]
16. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus.
Hanefeld M
J Diabetes Complications; 1998; 12(4):228-37. PubMed ID: 9647342
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
[TBL] [Abstract][Full Text] [Related]
18. Acarbose for non-insulin-dependent diabetes mellitus.
Drug Ther Bull; 1994 Jul; 32(7):51-3. PubMed ID: 7635034
[TBL] [Abstract][Full Text] [Related]
19. Predictors of persistence of use of the novel antidiabetic agent acarbose.
Catalan VS; Couture JA; LeLorier J
Arch Intern Med; 2001 Apr; 161(8):1106-12. PubMed ID: 11322845
[TBL] [Abstract][Full Text] [Related]
20. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
